Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
Open Access
- 13 November 2017
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 472 (3) , 395-405
Abstract
Claudin-2 is a trans-membrane protein—component of tight junctions in epithelial cells. Elevated claudin-2 expression has been reported in colorectal cancer (CRC). The aim of this study was to investigate the expression patterns of claudin-2 in human CRC samples and analyze its association with clinical characteristics and treatment outcome. TMAs of primary tumors from two cohorts of metastatic CRC (mCRC) were used. Claudin-2 IHC staining was evaluated in a semi-quantitative manner in different regions and cell types. Claudin-2 expression was also analyzed by immunofluorescence in primary cultures of human CRC cancer-associated fibroblasts (CAFs). Initial analyses identified previously unrecognized expression patterns of claudin-2 in CAFs of human CRC. Claudin-2 expression in CAFs of the invasive margin was associated with shorter progression-free survival. Subgroup analyses demonstrated that the survival associations occurred among cases that received 5-FU+oxaliplatin combination treatment, but not in patients receiving 5-FU±irinotecan. The finding was validated by analyses of the independent cohort. In summary, previously unreported stromal expression of claudin-2 in CAFs of human CRC was detected together with significant association between high claudin-2 expression in CAFs and shorter survival in 5-FU+oxaliplatin-treated mCRC patients.Keywords
Funding Information
- Cancerfonden
- Radiumhemmets Forskningsfonder
- STARGET Linné-grant from Swedish Research Council
- Svenska Institutet
- Merck KGaA
- Sanofi, Oslo
- Kreftforeningen
This publication has 32 references indexed in Scilit:
- Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitisNature Genetics, 2012
- Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factorsClinical Epidemiology, 2012
- Claudins and Other Tight Junction Proteins2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- BRAF mutation is a prognostic biomarker for colorectal liver metastasectomyJournal of Surgical Oncology, 2012
- Claudin‐1, Claudin‐2 and Claudin‐11 Genes Differentially Associate with Distinct Types of Anti‐inflammatory Macrophages In vitro and with Parasite‐ and Tumour‐elicited Macrophages In vivoScandinavian Journal of Immunology, 2012
- Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single InstitutionJournal of the American College of Surgeons, 2010
- Cancer-associated fibroblasts and tumor growth – bystanders turning into key playersCurrent Opinion in Genetics & Development, 2009
- Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumoursHistopathology, 2005
- Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convectionMicrovascular Research, 1989